Elevated hepatocyte growth factor levels in osteoarthritis osteoblasts contribute to their altered response to bone morphogenetic protein-2 and reduced mineralization capacity by E. Abed et al.
Elevated hepatocyte growth factor levels in osteoarthritis
osteoblasts contribute to their altered response to bone
morphogenetic protein-2 and reduced mineralization
capacity
Submitted by a.bergoend on Fri, 04/24/2015 - 11:06
Titre
Elevated hepatocyte growth factor levels in osteoarthritis osteoblasts contribute to
their altered response to bone morphogenetic protein-2 and reduced mineralization
capacity
Type de
publication Article de revue
Auteur Abed, E. [1], Bouvard, Béatrice [2], Martineau, X. [3], Jouzeau, Jean-Yves [4], Reboul,P. [5], Lajeunesse, D. [6]
Editeur Elsevier
Type Article scientifique dans une revue à comité de lecture
Année 2015
Langue Anglais
Date Jan-06-2015
Pagination 111-119
Volume 75
Titre de la
revue BONE
ISSN 8756-3282
Mots-clés Bone morphogenetic protein-2 [7], Hepatocyte Growth Factor [8], Osteoarthritis [9],Osteoblasts [10], Wnt signaling [11]
Résumé en
anglais
PURPOSE:
Clinical and in vitro studies suggest that subchondral bone sclerosis due to abnormal
osteoblasts is involved in the progression of osteoarthritis (OA). Human osteoblasts
isolated from sclerotic subchondral OA bone tissue show an altered phenotype, a
decreased canonical Wnt/ß-catenin pathway, and a reduced mineralization in vitro as
well as in vivo. These alterations were linked with an abnormal response to BMP-2.
OA osteoblasts release factors such as the hepatocyte growth factor (HGF) that
contribute to cartilage loss whereas chondrocytes do not express HGF. HGF can
stimulate BMP-2 expression in human osteoblasts, however, the role of HGF and its
effect in OA osteoblasts remains unknown. Here we investigated whether elevated
endogenous HGF levels in OA osteoblasts are responsible for their altered response
to BMP-2.
METHODS:
We prepared primary human subchondral osteoblasts using the sclerotic medial
portion of the tibial plateaus of OA patients undergoing total knee arthroplasty, or
from tibial plateaus of normal individuals obtained at autopsy. The expression of HGF
was evaluated by qRT-PCR and the protein production by western blot analysis. HGF
expression was reduced with siRNA technique whereas its activity was inhibited
using the selective inhibitor PHA665752. Alkaline phosphatase activity (ALPase) and
osteocalcin release were measured by substrate hydrolysis and EIA respectively.
Canonical Wnt/β-catenin signaling (cWnt) was evaluated both by target gene
expression using the TOPflash TCF/lef luciferase reporter assay and western blot
analysis of β-catenin levels in response to Wnt3a stimulation. Mineralization in
response to BMP-2 was evaluated by alizarin red staining.
RESULTS:
The expression of HGF was increased in OA osteoblasts compared to normal
osteoblasts and was maintained during their in vitro differentiation. OA osteoblasts
released more HGF than normal osteoblasts as assessed by western blot analysis.
HGF stimulated the expression of TGF-β1. BMP-2 dose-dependently (1 to 100ng/ml)
stimulated both ALPase and osteocalcin in normal osteoblasts whereas, it inhibited
them in OA osteoblasts. HGF-siRNA treatments reversed this response in OA
osteoblasts and restored the BMP-2 response. cWnt is reduced in OA osteoblasts
compared to normal, and HGF-siRNA treatments increased cWnt in OA osteoblasts
almost to normal. Smad1/5/8 phosphorylation in response to BMP-2, which is reduced
in OA osteoblasts, was corrected when these cells were treated with PHA665752. The
BMP-2-dependent mineralization of OA osteoblasts, which is also reduced compared
to normal, was only partially restored by PHA665752 treatment whereas 28days
treatment with HGF reduced the mineralization of normal osteoblasts.
CONCLUSION:
OA osteoblasts expressed more HGF than normal osteoblasts. Increased endogenous
HGF production in OA osteoblasts stimulated the expression of TGF-β1 and reduced
their response to BMP-2. Inhibiting HGF expression or HGF signaling restored the
response to BMP-2 and Smad1/5/8 signaling. In addition, decreased HGF signaling
partly corrects the abnormal mineralization of OA osteoblasts while increased HGF
prevents the normal mineralization of normal osteoblasts. In summary, we
hypothesize that sustained elevated HGF levels in OA osteoblasts drive their
abnormal phenotype and is implicated in OA pathophysiology.
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